Stevanato Group S.p.A.

NYSE:STVN

Medical - Instruments & Supplies

Healthcare
$15.36 +3.90%

+$0.67 today

Market cap
$4.20B
Beta
0.78
P/E (TTM)
29.9
EPS (TTM)
$0.52
Dividend yield
0.35%
52W Low $12.89High $28.00

Volume 0.61M

Average 0.52M

STVN Net Income

Bottom-line profit, the starting point for calculating cash from operations.

Stevanato Group S.p.A.NYSE: STVN

Net Income · Q2 FY2026 · quarter ended Jun 2026

Net income declines year over year

Q2 FY2026 net income of €38.12M fell 2.5% year over year, ahead of the -3.3% change in trailing-twelve-month net income. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at -10.5% a year.

Context

  • Net income amounted to 11.8% of revenue in FY2025, down 2.7 pp from a year earlier.
  • Net income increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 10 analysts of €149.98M (+11.7%) for the fiscal year ending Dec 2026, a step up from the -16.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
€38.12M-2.9% QoQ
Last fiscal yearDec 2025
€134.32M-16.2% YoY
LTMJun 2026
€173.64M-3.3% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.5%-11.7%-9.1 pp
1 year-16.2%+11.7%+27.9 pp
3-year CAGR-10.5%+11.5%+22.1 pp
5-year CAGR+20.4%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

EUR · from the cash flow

Latest · FY2025
134.32M EUR
Year-over-year change
-16.2%
4-year CAGR
-5.1%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How STVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -3.3% is the 5th highest of 11, against a peer median of -13.3%.
  • Net income amounts to 14.2% of revenue for STVN, versus a peer median of 9.9%.
STVN Competitors
Net Income for STVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MASIMasimo CorporationLTM Apr 2026$652.6M USD+325.2%—41.9%
AVTRAvantor, Inc.LTM Jun 2026$578M USD-184.1%—8.8%
NUVLNuvalent, Inc.LTM Mar 2026$450.07M USD+49.6%+73.2%—
BTSGBrightSpring Health Services, Inc. Common StockLTM Sep 2026$336.27M USD+164.4%—2.2%
TFXTeleflex IncorporatedLTM Jun 2026$320.9M USD-267.2%-45.6%12.3%
ATRAptarGroup, Inc.LTM Jun 2026$307.89M USD-21.3%+17.9%7.8%
CHEChemed CorporationLTM Jun 2026$274.99M USD-5.3%+2.0%10.6%
AXSMAxsome Therapeutics, Inc.LTM Jun 2026$191.64M USD-22.4%-0.7%24.7%
STVNStevanato Group S.p.A.LTM Jun 2026€173.64M EUR-3.3%-10.5%14.2%
BLCOBausch + Lomb CorporationLTM Jun 2026$167M USD-36.5%—3.1%
MMSIMerit Medical Systems, Inc.LTM Sep 2026$160.12M USD+35.2%+19.9%9.9%
Peer median (excluding STVN) —-13.3%+10.0%9.9%

Competitors are the stored peer set for STVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income165.67M187.64M189.55M160.29M134.32M
Depreciation & Amortization56.38M64.82M78.48M80.65M88.57M
Deferred Income Tax00000
Stock-Based Compensation00000
Change in Working Capital(41.63M)(117.74M)(102.48M)(17.41M)48.63M
Accounts Receivables(54.77M)(46.42M)(93.86M)(3.83M)855.83K
Inventory(31.2M)(107.37M)(113.59M)12.31M(39.82M)
Accounts Payables44.34M36.05M104.97M(25.89M)87.59M
Other Working Capital00000
Other Non-Cash Items(47.09M)(31.41M)(60.34M)(67.76M)3.27M
Operating Cash Flow133.34M103.31M105.21M155.78M274.79M
Capital Expenditures(113.18M)(243.13M)(441.93M)(313.57M)(253.35M)
Acquisitions (Net)14.81M0(3.59M)(175K)1.79M
Purchases of Investments00000
Sales of Investments773K31K00241.09K
Other Investing Activities(4.32M)(7.95M)15.6M(7.44M)0
Investing Cash Flow(96.43M)(242.95M)(421.22M)(310.21M)(262.15M)
Debt Repayment(120.18M)(31.04M)172.57M27.91M41.38M
Common Stock Issued380.09M00169.77M0
Common Stock Repurchased00000
Dividends Paid(11.2M)(13.5M)(14.29M)(14.46M)(14.16M)
Other Financing Activities6.13M0(250K)0(6.03M)
Financing Cash Flow254.85M(44.54M)158.03M183.22M21.19M
Effect of Forex Changes3.68M1.88M(1.16M)(115K)10.11M
Net Change in Cash295.44M(182.3M)(159.14M)28.67M43.94M
Free Cash Flow20.16M(139.82M)(336.72M)(157.8M)21.44M

Stevanato Group S.p.A.

NYSE:STVN

Intrinsic Alpha fair value

Locked

Current Price

$15.36

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.